Profiling of serum metabolites in advanced colon cancer using liquid chromatography‑mass spectrometry

Zhang,Yang; Du,Yechao; Song,Zheyu; Liu,Suoning; Li,Wei; Wang,Daguang; Suo,Jian

doi:10.3892/ol.2020.11510

Profiling of serum metabolites in advanced colon cancer using liquid chromatography‑mass spectrometry

Authors:
- Yang Zhang
- Yechao Du
- Zheyu Song
- Suoning Liu
- Wei Li
- Daguang Wang
- Jian Suo
View Affiliations

Affiliations: The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: April 3, 2020 https://doi.org/10.3892/ol.2020.11510
Pages: 4002-4010
Copyright : © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lymph node metastasis remains a key factor that affects the prognosis of patients with colon cancer. The aim of the present study was to identify and evaluate serum metabolites as biomarkers for the detection of tumor lymph node metastasis and the prediction of patient survival. The present study analyzed the metabolites in the serum of patients with advanced colon cancer both with and without lymph node metastasis. Blood samples from 104 patients with stage T3 colon cancer were collected and analyzed using liquid chromatography‑mass spectrometry. The metabolites were structurally confirmed with data from the Human Metabolome Database. The association between the serum metabolites and the clinicopathological characteristics and survival time of patients from the present study was analyzed. Overall, 227 different metabolites were identified in the serum of patients with stage T3 colon cancer with or without lymph node metastasis. Furthermore, 17 of these metabolites may potentially distinguish those patients with lymph node metastasis from those patients without. In addition, five factors, including abscisic acid, calcitroic acid and glucosylsphingosine presence in the serum, age and sex, were identified as independent predictors for lymph node metastasis (P<0.05). Furthermore, three factors, including abscisic acid, calcitroic acid and glucosylsphingosine presence in the serum were independent predictors for patient survival (P<0.05). In conclusion, the serum levels of abscisic acid, calcitroic‑acid and glucosylsphingosine may be considered as potential biomarkers to predict the occurrence of lymph node metastasis and the survival time of patients with colon cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, et al: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 8:4844–4850. 2009. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
4	Wang J, Yan F, Zhao Q, Zhan F, Wang R, Wang L, Zhang Y and Huang X: Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer. Sci Rep. 7:41502017. View Article : Google Scholar : PubMed/NCBI
5	Jiménez B, Mirnezami R, Kinross J, Cloarec O, Keun HC, Holmes E, Goldin RD, Ziprin P, Darzi A and Nicholson JK: 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic ‘field-effects’ enables colorectal cancer staging and prognostication. J Proteome Res. 12:959–968. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kotronoulas G, Papadopoulou C, Burns-Cunningham K, Simpson M and Maguire R: A systematic review of the supportive care needs of people living with and beyond cancer of the colon and/or rectum. Eur J Oncol Nurs. 29:60–70. 2017. View Article : Google Scholar : PubMed/NCBI
7	Pignone M and Levin B: Recent developments in colorectal cancer screening and prevention. Am Fam Physician. 66:297–302. 2002.PubMed/NCBI
8	Kronborg O: Colon polyps and cancer. Endoscopy. 36:3–7. 2004. View Article : Google Scholar : PubMed/NCBI
9	Pellino G, Simillis C, Kontovounisios C, Baird DL, Nikolaou S, Warren O, Tekkis PP and Rasheed S: Colorectal cancer diagnosed during pregnancy: Systematic review and treatment pathways. Eur J Gastroenterol Hepatol. 29:743–753. 2017. View Article : Google Scholar : PubMed/NCBI
10	Seeber A and Gastl G: Targeted Therapy of Colorectal Cancer. Oncol Res Treat. 39:796–802. 2016. View Article : Google Scholar : PubMed/NCBI
11	Pohl M and Schmiegel W: Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. Dig Dis. 34:574–579. 2016. View Article : Google Scholar : PubMed/NCBI
12	Courant F, Antignac JP, Monteau F and Le Bizec B: Metabolomics as a potential new approach for investigating human reproductive disorders. J Proteome Res. 12:2914–2920. 2013. View Article : Google Scholar : PubMed/NCBI
13	Manna SK, Krausz KW, Bonzo JA, Idle JR and Gonzalez FJ: Metabolomics reveals aging-associated attenuation of noninvasive radiation biomarkers in mice: Potential role of polyamine catabolism and incoherent DNA damage-repair. J Proteome Res. 12:2269–2281. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wang X, Yang B, Sun H and Zhang A: Pattern recognition approaches and computational systems tools for ultra performance liquid chromatography-mass spectrometry-based comprehensive metabolomic profiling and pathways analysis of biological data sets. Anal Chem. 84:428–439. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhang A, Sun H, Wang P, Han Y and Wang X: Modern analytical techniques in metabolomics analysis. Analyst (Lond). 137:293–300. 2012. View Article : Google Scholar
16	Mondul AM, Moore SC, Weinstein SJ, Männistö S, Sampson JN and Albanes D: 1-stearoylglycerol is associated with risk of prostate cancer: Results from serum metabolomic profiling. Metabolomics. 10:1036–1041. 2014. View Article : Google Scholar : PubMed/NCBI
17	Aboud OA and Weiss RH: New opportunities from the cancer metabolome. Clin Chem. 59:138–146. 2013. View Article : Google Scholar : PubMed/NCBI
18	Ritchie SA, Ahiahonu PWK, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, et al: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: Implications for early screening and detection. BMC Med. 8:132010. View Article : Google Scholar : PubMed/NCBI
19	Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, et al: Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer. 123:4066–4074. 2017. View Article : Google Scholar : PubMed/NCBI
20	Deng L, Gu H, Zhu J, Nagana Gowda GA, Djukovic D, Chiorean EG and Raftery D: Combining NMR and LC/MS using backward variable elimination: Metabolomics analysis of colorectal cancer, polyps, and healthy controls. Anal Chem. 88:7975–7983. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Abu Zaid M, Chiorean EG and Raftery D: Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring. Anal Bioanal Chem. 407:7857–7863. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG and Raftery D: Colorectal cancer detection using targeted serum metabolic profiling. J Proteome Res. 13:4120–4130. 2014. View Article : Google Scholar : PubMed/NCBI
23	Uchiyama K, Yagi N, Mizushima K, Higashimura Y, Hirai Y, Okayama T, Yoshida N, Katada K, Kamada K, Handa O, et al: Serum metabolomics analysis for early detection of colorectal cancer. J Gastroenterol. 52:677–694. 2017. View Article : Google Scholar : PubMed/NCBI
24	Nishiumi S, Kobayashi T, Kawana S, Unno Y, Sakai T, Okamoto K, Yamada Y, Sudo K, Yamaji T, Saito Y, et al: Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry. Oncotarget. 8:17115–17126. 2017. View Article : Google Scholar : PubMed/NCBI
25	Singletary SE, Greene FL and Sobin LH: Classification of isolated tumor cells: Clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 98:2740–2741. 2003. View Article : Google Scholar : PubMed/NCBI
26	Li W, Ye F, Wang D, Sun X, Tong W, Lian G, Jiang J, Suo J and Zhang DY: Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer. 132:1851–1859. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wang D, Ye F, Sun Y, Li W, Liu H, Jiang J, Zhang Y, Liu C, Tong W, Gao L, et al: Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am J Pathol. 179:1657–1666. 2011. View Article : Google Scholar : PubMed/NCBI
28	Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, et al: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 11:1354–1363. 2012. View Article : Google Scholar : PubMed/NCBI
29	Vahabi F, Sadeghi S, Arjmand M, Mirkhani F, Hosseini E, Mehrabanfar M, Hajhosseini R, Iravani A, Bayat P and Zamani Z: Staging of colorectal cancer using serum metabolomics with 1HNMR Spectroscopy. Iran J Basic Med Sci. 20:835–840. 2017.PubMed/NCBI
30	Yang W, Mu T, Jiang J, Sun Q, Hou X, Sun Y, Zhong L, Wang C and Sun C: Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC/Q-TOF MS. Cell Physiol Biochem. 51:1134–1148. 2018. View Article : Google Scholar : PubMed/NCBI
31	Ma Y, Zhang P, Wang F, et al: An integrated proteomics and metabolome approach for defining oncofetal biomarkers in the CC. Ann Surg. 255:720–730. 2012. View Article : Google Scholar : PubMed/NCBI
32	Carloni V, Luong TV and Rombouts K: Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: More complicated than ever. Liver Int. 34:834–843. 2014. View Article : Google Scholar : PubMed/NCBI
33	Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, Lonardi S, Friso ML, Mescoli C, Zagonel V, et al: Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer. 108:278–284. 2013. View Article : Google Scholar : PubMed/NCBI
34	Koga Y, Yamazaki N, Yamamoto Y, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M and Matsumura Y: Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 22:1844–1852. 2013. View Article : Google Scholar : PubMed/NCBI
35	Zheng X, Xie G and Jia W: Metabolomic profiling in colorectal cancer: Opportunities for personalized medicine. Per Med. 10:741–755. 2013. View Article : Google Scholar : PubMed/NCBI
36	Wang H, Tso VK, Slupsky CM and Fedorak RN: Metabolome and detection of CC in humans: A systematic review. Future Oncol. 6:1395–1406. 2010. View Article : Google Scholar : PubMed/NCBI
37	Bell SJ: The Effect of Vitamin D3 on Hepcidin and IL-8 Expression in Monocytes. J Hematol (Brossard). 2:1–7. 2013.
38	Liang CJ, Yen YH, Hung LY, Wang SH, Pu CM, Chien HF, Tsai JS, Lee CW, Yen FL and Chen YL: Thalidomide inhibits fibronectin production in TGF-β1-treated normal and keloid fibroblasts via inhibition of the p38/Smad3 pathway. Biochem Pharmacol. 85:1594–1602. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hedger MP, Winnall WR, Phillips DJ and de Kretser DM: The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm. 85:255–297. 2011. View Article : Google Scholar : PubMed/NCBI
40	Xu Q, Tan Y, Zhang K and Li Y: Crosstalk between p38 and Smad3 through TGF-β1 in JEG-3 choriocarcinoma cells. Int J Oncol. 43:1187–1193. 2013. View Article : Google Scholar : PubMed/NCBI
41	Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H and Ishii M: Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci USA. 110:7009–7013. 2013. View Article : Google Scholar : PubMed/NCBI
42	Yang S and Qiu MX: Progress on the development of relations of Smad4 protein and tumorigenesis. Pract J Clin Med. 1:158–160,161. 2015.(In Chinese).